Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00572728 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 90
- Enrollment target
NCT00572728: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00572728 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 90 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00572728, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 90 participants
- Enrollment target
Study Summary
This phase II trial studies how well 3'-deoxy-3'-18F fluorothymidine (18F-FLT) positron emission tomography (PET)/computed tomography (CT) works in predicting response in patients receiving chemotherapy and undergoing surgery for breast cancer that has spread from where it started to nearby tissue or lymph nodes. Diagnostic procedures, such as 18F-FLT PET/CT, may help in learning how well chemotherapy works to kill breast cancer cells before surgery and help doctors plan the best treatment.
Interventions
- PROCEDURE CT
- PROCEDURE PET
- DRUG 18F-FLT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2008-12 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00572728
The ClinicalTrials.gov registry entry for NCT00572728 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which CT is the first listed.
NCT00572728 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00572728 about?
NCT00572728 is a clinical study titled "Phase II Study of Fluorine-18 3'-Deoxy-3'-Fluorothymidine (F-18-FLT) in Invasive Breast Cancer". This phase II trial studies how well 3'-deoxy-3'-18F fluorothymidine (18F-FLT) positron emission tomography (PET)/computed tomography (CT) works in predicting response in patients receiving chemotherapy and undergoing surgery for breast cancer that has spread from where it started to nearby tissue o...
What is the current status of trial NCT00572728?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 90 participants. The study started on 2008-12. Estimated completion is 2014-10.
What interventions are being tested in trial NCT00572728?
The interventions under investigation include: CT (PROCEDURE), PET (PROCEDURE), 18F-FLT (DRUG).
Who is sponsoring clinical trial NCT00572728?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.